Sort
48,018 grants matching “immunotherapy”
Using the IL-1R1 and its ligands to optimize the T cell immune response to cancer
$618,308Thomas S. Kupper · Brigham And Women'S Hospital · R01 · FY2025 · CA
Harnessing TNFa Signaling To Improve Therapeutic Response In Pancreatic Cancer
$618,273Kian H Lim · Washington University · R01 · FY2023 · CA
Developing a novel combination immunotherapy for triple-negative breast cancer
$618,212Naoto T Ueno · University Of Hawaii At Manoa · R01 · FY2024 · CA
Long-Term Cardiovascular Sequelae of Cancer Immunotherapies
$618,167Javid J Moslehi · University Of California, San Francisco · R01 · FY2023 · HL
Glycosylation and Immune Evasion in Urologic Tumors
$618,139Sharon Pitteri · Stanford University · U01 · FY2020 · CA
Triggering Aberrant RNA Processing for RCC Therapy
$618,057William Y Kim · Univ Of North Carolina Chapel Hill · R01 · FY2024 · CA
Triggering Aberrant RNA Processing for RCC Therapy
$618,056William Y Kim · Univ Of North Carolina Chapel Hill · R01 · FY2025 · CA
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer
$618,012Maximilian Diehn · Stanford University · R01 · FY2021 · CA
Structure-based inhibition of chemokine signaling in the inflamed pancreas
$617,998Brian F Volkman · Medical College Of Wisconsin · R01 · FY2024 · DK
Clinical Trials Exploiting NK Cell Activity
$617,975Daniel J Weisdorf · University Of Minnesota · P01 · FY2016 · CA
Drug eluting injectable biomaterials for next generation chemoembolization
$617,904Rahmi Oklu · Mayo Clinic Arizona · R01 · FY2025 · CA
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS
$617,796Ernesto Guccione · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS
$617,796Ernesto Guccione · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · CA
Cancer Stem Cells in Cholangiocarcinoma
$617,755Changqing Xie · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Assessing Benefits and Harms of Medical Cannabis and Cannabinoid Use in Breast Cancer Patients During and After Treatments
$617,738Jennifer J Hu · University Of Miami School Of Medicine · U01 · FY2024 · CA
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy
$617,715Brent Allen Hanks · Univ Of North Carolina Chapel Hill · R37 · FY2025 · CA
Molecular Mechanisms of Adjuvant Triplet Combinations
$617,466Nicolas Chevrier · University Of Chicago · U01 · FY2023 · AI
PET Studies of Serotonin and Amyloid in MCI
$617,426Gwenn S Smith · Johns Hopkins University · R01 · FY2011 · AG
Programmable encapsulation systems to improve delivery of therapeutic bacteria
$617,386Tal Danino · Columbia Univ New York Morningside · R01 · FY2024 · EB
Co-Clinical Research Resource for Imaging Tumor Associated Macrophages
$617,354Heike Elizabeth Daldrup-Link · Stanford University · U24 · FY2024 · CA
Rapamycin and IL-21 Conditioned CD8+ T Cells for Adoptive Cellular Therapy of Ov
$617,258Protul Shrikant · Roswell Park Cancer Institute Corp · P50 · FY2015 · CA
HIFU-immunotherapy in pancreatic cancer
$617,146Katherine W Ferrara · Stanford University · R01 · FY2022 · CA
Identification of human tumor-associated antigens
$617,092Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Analyses of human T regulatory cells
$617,092Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Host Response to TB and AIDS
$617,040New York University School Of Medicine · R01 · FY2003 · HL